The global enteral feeding devices market was valued at approximately USD 4.3 billion in 2023 and is projected to experience steady growth, with a compound annual growth rate (CAGR) of 5.0% anticipated from 2024 to 2030. This growth can largely be attributed to the increasing geriatric population, which has led to a rise in the incidence of chronic conditions such as diabetes, severe pancreatitis, and various gastrointestinal diseases. These health challenges are driving the demand for enteral feeding devices, as they play a crucial role in the nutritional management of affected individuals.
Additionally, the implementation of the “Feed Early Enteral Diet Adequately for Maximum Effect” (FEED ME) protocol in surgical trauma intensive care units (ICUs) across the United States is facilitating subsidies for these devices, further promoting their use. Technological innovations, including the introduction of tri-funnel replacement G-tubes and J-tubes designed with reverse balloon mechanisms, are also expected to contribute to market growth throughout the forecast period.
Gather more insights about the market drivers, restrains and growth of the Enteral Feeding Devices Market
Research from numerous studies published by the National Center for Biotechnology Information (NCBI) highlights that individuals aged 65 and older are at a heightened risk of developing chronic illnesses, including Parkinson’s disease and various nervous system disorders. The global demographic trend indicates that the population aged 60 years and above is projected to grow from approximately 1 billion in 2020 to about 1.4 billion by 2030, with expectations to double again by 2050, reaching around 2.1 billion. This demographic shift is resulting in a significant increase in elderly patients facing critical illnesses.
The prevalence of malnutrition and frailty among the geriatric population, particularly those with comorbidities such as stroke, depression, and dementia, is considerably high. This vulnerability is primarily due to age-related changes in body composition and muscle mass, which lead to a diminished ability to perform Activities of Daily Living (ADLs). Consequently, this increases the risk of falls and injuries among the elderly.
Indication Insights
In terms of market segmentation based on medical indications, the cancer care segment emerged as the dominant category, capturing a revenue share of 27.9% in 2023. Enteral feeding is also utilized for critically ill patients suffering from a range of other diseases and conditions, including Chronic Obstructive Pulmonary Disease (COPD), cystic fibrosis, and various respiratory disorders. For example, Pulmocare, a product developed by Abbott, serves as an enteral feed specifically formulated for patients with these conditions. Furthermore, enteral feeds can effectively address issues related to inflammation, postoperative stress, and infections, highlighting their versatility in clinical settings.
The orphan diseases segment is expected to grow at the fastest CAGR in the coming years. According to the Ministry of Health and Family Welfare (MoHFW) of the Government of India, approximately 300 million individuals worldwide are living with rare diseases, with around 72% of these conditions being genetic in nature. Notably, about 70% of these rare genetic diseases manifest during childhood. The growing awareness of enteral nutrition, coupled with an increasing number of diseases classified as orphan diseases, is anticipated to drive significant growth in this market segment over the forecast period. This aligns with the broader trend of enhancing nutritional care for patients with specialized medical needs, thereby positioning the enteral feeding devices market for continued expansion.
Order a free sample PDF of the Market Intelligence Study, published by Grand View Research.
